NLRP3 and metabolic disease: Oral treatment of TR improved the symptoms of metabolic disorders or gouty arthritis in wild‐type mice, but not in Nlrp3−/− mice, suggesting the beneficial effects of TR depend on its suppressive activity for NLRP3 inflammasome.